Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6

    CHENGDU, China, Aug. 31 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a biopharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics will participate in the Roth Fall Conference from September 1 - September 6 at Grand Wailea Resort Hotel, Maui, Hawaii.

    Dr. James Jiayuan Tong, Tianyin's Chief Financial Officer, Chief Business & Development Officer and Director is invited to present in two following panel discussions at the conference.

    CFO Essentials -- Updates And Practical Implications For CFOs of U.S.-Listed Chinese Companies

    Wednesday, September 1, 2:30 pm - 4:00 pm, Haleakala Ballroom

    China Social Infrastructure Panel

    Thursday, September 2, 10:00 am - 10:55 am, Haleakala Ballroom

    About Tianyin Pharmaceuticals

    Tianyin Pharmaceutical Co., Inc., headquartered at Chengdu, China, is a biopharmaceutical company that specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicines and branded generics. Tianyin currently manufactures a comprehensive portfolio of 56 products, of which 23 are listed in the national medicine reimbursement list, 7 are included in the essential drug list of China. Tianyin currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

    Safe Harbor Statement

    The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    Tianyin Pharmaceutical Co., Inc.
     James Jiayuan Tong M.D. Ph.D.
     Chief Financial Officer, Chief Business & Development Officer
     Director
     Add:   23rd Floor Unionsun Yangkuo Plaza
            No 2 Block 3 South Renmin Road
            Chengdu, 610041
            China
     Tel:   +86-28-8551-6696 (Chengdu, China)
            +86-134-3655-0011 (China)
            +1-949-350-6999 (U.S.)
     Email: Dr.Tong@tianyinpharma.com
     Web:   http://www.tianyinpharma.com